---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134767"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:56:41.683140+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q1 net loss narrows to $8M; SNS-101 Phase 1 dose escalation complete, no DLTs

## Summary
- Net loss of $8.0M for Q1 2024 vs $10.2M in Q1 2023; R&D spend $4.9M, G&A $3.8M.
- Cash, cash equivalents and marketable securities $58.1M at March 31, 2024; runway into Q4 2025.
- SNS-101 Phase 1/2 dose escalation completed: 16 patients monotherapy, 18 combination; no DLTs observed.
- Topline data at ASCO 2024; dose expansion enrolling; end-of-Phase 1 FDA meeting expected by end of 2024.

## SEC filing metadata
- accession: 0001193125-24-134767
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/0001193125-24-134767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/d836832d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134767
- JSON: https://secwatch.observer/filing/0001193125-24-134767.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134767.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $8.0 million for the quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss was $8.0 million for the quarter ended March 31, 2024
  - Result: reported results
  source text: Net loss was $8.0 million for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/0001193125-24-134767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.